SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth. SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth

Malignant rhabdoid tumor (MRT) is a highly malignant and often lethal childhood cancer. MRTs are genetically defined by bi-allelic inactivating mutations in SMARCB1, a member of the BRG1/BRM-associated factors (BAF) chromatin remodeling complex. Here, we studied derailed regulatory landscapes as a consequence of SMARCB1 loss in the context of MRT. Our multi-omics approach on patient-derived MRT organoids revealed a dramatic reshaping of the regulatory landscape upon SMARCB1 reconstitution. Chromosome conformation capture experiments subsequently revealed patient-specific looping of distal enhancer regions with the promoter of the MYC oncogene and validation of this data in patients with combined single-cell RNA-seq and ATAC-seq. Overall design: Paired scRNA and scATAC-seq on the same cell of primary malignant rhabdoid tumor samples (viably frozen or snapfrozen) >>>Submitter states: raw data are unavailable due to patient privacy concerns.<<<